Effect of A Kappa- opioid Receptor Agonist U50488H Given at Early Reperfusion Phase in Isolated Rat Hearts

Yong Cheol Lee, M.D., Young Ho Jang, M.D., Jin Mo Kim, M.D., Ae Ra Kim, M.D., Chan Jin Kim, M.D., and Yoon Nyun Kim, M.D.*

Background: The experiment was performed to determine the role of \( \kappa \)-opioid receptor (OR) agonist U50488H given at early reperfusion.

Methods: Isolated hearts were subjected to 30 minutes of regional ischemia and 120 minutes of reperfusion. Hearts were assigned randomly to one of the three groups: 1) Control (n = 9), 2) U50-1 (n = 8); 1 \( \mu \)M of U50488H, and 3) U50-10 (n = 8); 10 \( \mu \)M of U50488H. U50488 was perfused for a period of 5 min before and 30 min after reperfusion.

Results: U50488H significantly reduced infarct size as a percentage of ischemic area (12.2 ± 1.9% in U50-1 and 7.2 ± 1.7% in U50-10, P < 0.001) compared to the control hearts (27.2 ± 1.2%). After 2 hrs of reperfusion, left ventricular developed pressure was significantly recovered by U50488H (62.6 ± 5.7% in U50-1 and 68.6 ± 4.7% in U50-10, P = 0.018 and 0.002, respectively) compared to the control (46.3 ± 4.4%). Rate-pressure product was improved by 10 \( \mu \)M U50488H (62.3 ± 5.5%, P = 0.007) but not by 1 \( \mu \)M U50488H (50.0 ± 4.1%) compared to the control (44.7 ± 4.5%). U50488H significantly increased the \( +\Delta P/dt_{\text{max}} \) (77.9 ± 5.5% in U50-1 and 78.0 ± 4.3 in U50-10, P = 0.005 and 0.001 vs. control, respectively). The \( -\Delta P/dt_{\text{min}} \) also improved by 10 \( \mu \)M U50488H (64.7 ± 4.8%, P = 0.003) compared to control (47.0 ± 2.7%).

Conclusions: U50488H given at early reperfusion phase reduces both infarct size and myocardial stunning in isolated rat hearts.

Key Words: ischemia, myocardium, opioid receptor, reperfusion.

INTRODUCTION

Opioids have been widely used in the anesthesia field as anesthetic adjuncts or for pain control. Because pretreatment is seldom possible in an acute myocardial infarction, pharmacological therapies targeting reperfusion has generated considerable recent interest. In this regard, opioids may play a key strategic role because these drugs are widely used in clinical field and can protect against post-ischemic myocardial injury at the time of reperfusion.1)

Based on binding studies, there is evidence that both \( \delta \)- and \( \kappa \)-opioid receptors (OR) are located in the myocardium.2,3) It has previously been demonstrated that the activation of OR by ischemic preconditioning (IPC) or by opioid-induced pharmacological pretreatment provides cardioprotection against ischemia-reperfusion (I/R) injury via activation of the \( \delta \)-OR subtypes, especially the \( \delta_1 \)-OR.4,6) However, the cardioprotective role of \( \kappa \)-OR remains unclear and there continues to be controversy regarding its role in myocardial I/R injury.6-9) Recently, Wang et al.10) demonstrated that ischemic postconditioning (Post-C) improved cardiodynamics in isolated rat hearts. They suggested that the functional recovery by Post-C was induced via activation of \( \kappa \)-OR and opening of mitochondrial K\(_{\text{ATP}}\) (mK\(_{\text{ATP}}\)) channels. Therefore, it is highly suggested that the direct treatment of U50488H, a selective \( \kappa \)-OR agonist, given at early reperfusion might also improve cardiodynamic parameters in I/R induced hearts.

The objective of this study was to investigate the protective effect of U50488H on infarct limitation and post-reperfusion contractile recovery during the reperfusion phase in isolated perfused rat hearts.
Fig. 1. Experimental protocol. For measurement of hemodynamic data and infarct size by \(\kappa\)-opioid receptor activation, isolated rat hearts are exposed to 30 min ischemia followed by 2 hrs reperfusion. Two concentrations of \(\kappa\)-opioid receptor agonist U50488H (1 and 10 \(\mu\)M) are perfused for a period of 5 min before and 30 min after reperfusion (hatched rectangle).
Yong Cheol Lee, et al: Kappa-opioid Receptor and Myocardial Reperfusion

Fig. 2. Area at necrosis (AN) as percentage of area at risk (AAR) as evaluated by triphenyltetrazolium chloride staining following 30 min regional ischemia and 2 hrs reperfusion in isolated rat heart model. Rat hearts were subjected to control and treated with 1 (U50-1) or 10 μM (U50-10) of U50488H. Both concentrations of U50488H given at early reperfusion phase significantly decrease AN/AAR. Values are expressed as mean ± SEM. *: P < 0.001 vs. Control.

Table 1. Morphometrics for Isolated Rat Hearts

<table>
<thead>
<tr>
<th>Group</th>
<th>Body weight (gm)</th>
<th>Heart weight (gm)</th>
<th>LV volume (cm³)</th>
<th>AAR volume (cm³)</th>
<th>AAR/LV (%)</th>
<th>AN volume (cm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 9)</td>
<td>305.0 ± 5.8</td>
<td>1.42 ± 0.02</td>
<td>0.519 ± 0.020</td>
<td>0.303 ± 0.014</td>
<td>60.8 ± 2.9</td>
<td>0.082 ± 0.004</td>
</tr>
<tr>
<td>U50-1 (n = 8)</td>
<td>307.8 ± 9.8</td>
<td>1.42 ± 0.03</td>
<td>0.498 ± 0.019</td>
<td>0.291 ± 0.020</td>
<td>59.2 ± 5.1</td>
<td>0.036 ± 0.005*</td>
</tr>
<tr>
<td>U50-10 (n = 8)</td>
<td>301.9 ± 4.8</td>
<td>1.40 ± 0.01</td>
<td>0.486 ± 0.029</td>
<td>0.279 ± 0.019</td>
<td>59.2 ± 7.5</td>
<td>0.022 ± 0.006*</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. n: number of hearts. LV: left ventricle, AAR: area at risk, AN: area at necrosis, U50-1: 1 μM U50488H, U50-10: 10 μM U50488H. There were no differences in body weight, heart weight, volumes of LV and AAR, and AAR/LV among groups. *: P < 0.001 vs. Control.

the compound was diluted with KH solution to the required final concentrations.

**Determination of area at risk and infarct size**

At the end of each experiment (2 hrs after reperfusion), the area at risk (AAR) and area at necrosis (AN) were measured as described in our previous study. In brief, the LCA perfusion circuit was reocluded, and diluted fluorescent polymer microspheres with 2–9 μm diameter (Duke Scientific Corp., USA) were infused to demarcate the AAR as the tissue without fluorescence. The hearts were weighed, frozen at −20°C for 1–3 hrs, and cut into 2 mm thick transverse slices using a rat heart slice matrix (Zivic Instruments, USA). The slices were incubated in 1% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich Chemical, USA) in sodium phosphate buffer (pH = 7.4) at 37°C for 20 min. The slices were immersed in 10% formalin to enhance the contrast between viable (red) and necrotic (pale) tissue and then compressed to a uniform 2 mm thickness by placing them (basal side) between two glass plates separated by a 2 mm space. The myocardial AAR was identified by illuminating the slices with U.V. light. The infarcted (unstained) and risk (no fluorescent area) zone regions were traced on a clear acetate transparent sheet and quantified with the UTHSCSA Image Tool 3.0 version. Volumes of the left ventricle, infarct zone, and risk zone were calculated by multiplying each area with slice thickness and summing the products. Infarct volume was expressed as a percentage of the AAR volume. All measurements were performed in a blinded fashion.

**Statistical analysis**

All values were expressed as means ± SEM. Data analysis was performed with SPSS 13.0 version. Data were analyzed using one-way analysis of variance with the Least Significant Difference test. Differences were considered to be statistically significant when P values were less than 0.05.

**RESULTS**

A total of 28 rat hearts were used for this experiment. All hearts were perfused within 30–40 seconds after excision. Three hearts were excluded from data analysis for the following reasons: a CF > 18 ml/min (1), LVDP < 80 mmHg (1), and HR < 250 beats/min (1) during the stabilization period. Therefore, we report the data for 25 successfully completed experiments (9 in Control, 8 in U50-1, and 8 in U50-10, respectively).

There were no significant group differences with respect to body weight, heart weight, and volumes of left ventricle and AAR (Table 1). As shown in Fig. 2, infarct size in the control hearts was 27.2 ± 1.2% of the AAR. Both concen-
Table 2. Baseline Coronary Flow and Hemodynamic Data

<table>
<thead>
<tr>
<th>Group</th>
<th>CF</th>
<th>HR</th>
<th>LVDP</th>
<th>RPP</th>
<th>+dP/dt_{max}</th>
<th>−dP/dt_{min}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 9)</td>
<td>14.0 ± 0.62</td>
<td>83.1 ± 8.1</td>
<td>103.5 ± 8.9</td>
<td>29.1 ± 2.3</td>
<td>2.69 ± 0.15</td>
<td>−2.67 ± 0.20</td>
</tr>
<tr>
<td>U50-1 (n = 8)</td>
<td>13.6 ± 0.92</td>
<td>92.1 ± 7.1</td>
<td>103.8 ± 3.8</td>
<td>30.2 ± 1.0</td>
<td>2.60 ± 0.10</td>
<td>−2.66 ± 0.10</td>
</tr>
<tr>
<td>U50-10 (n = 8)</td>
<td>14.0 ± 1.02</td>
<td>92.1 ± 7.1</td>
<td>103.8 ± 3.8</td>
<td>30.2 ± 1.0</td>
<td>2.60 ± 0.10</td>
<td>−2.66 ± 0.10</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. n: number of hearts. CF: coronary flow (ml/min), HR: heart rate (beats/min), LVDP: left ventricular developed pressure (mmHg), RPP: rate-pressure product (mmHg/min/103), +dP/dt_{max}: maximum positive left ventricular pressure derivative (mmHg/s/103), −dP/dt_{min}: minimum negative left ventricular pressure derivative (mmHg/s/103), U50-1: 1 μM U50488H, U50-10: 10 μM U50488H. There were no differences in baseline CF and hemodynamics among groups.

Fig. 3. Recovery of the left ventricular developed pressure (LVDP) and rate-pressure product (RPP) after 2 hrs reperfusion in isolated rat hearts. Rat hearts were subjected to control and treated with 1 (U50-1) or 10 μM (U50-10) of U50488H. U50488H treatment at reperfusion phase significantly increased the LVDP and RPP. Value are expressed as means ± SEM. *: P < 0.05 vs. control.

The treatment of a κ-OR agonist U50488H given at early reperfusion phase significantly reduced myocardial infarction (12.2 ± 1.9% in U50-1 and 7.2 ± 1.7% in U50-10, P < 0.001 vs. control).

The baseline hemodynamic data are summarized in Table 2. CF and hemodynamic indexes concerning HR, LVDP, RPP, +dP/dt_{max}, and −dP/dt_{min} were comparable in all groups under baseline conditions. The changes in LVDP and RPP after 2 hrs of reperfusion are presented in Fig. 3. LVDP was decreased to 46.3 ± 4.4% after 2 hrs of reperfusion compared to baseline value in control hearts. U50488H treatment at reperfusion phase significantly recovered the LVDP compared to the control hearts (62.6 ± 5.7% in U50-1, P = 0.018, 68.6 ± 4.7% in U50-10, P = 0.002). RPP in the control hearts was decreased to 44.7 ± 4.5% after 2 hrs of reperfusion. The attenuation of RPP was improved by 10 μM U50488H (62.3 ± 5.5%, P = 0.007) but not by 1 μM U50488H (50.0 ± 4.1%).

The changes in the recovery of the first derivative of left ventricular pressure after 2 hrs reperfusion are shown in Fig. 4. After 2 hrs of reperfusion, +dP/dt_{max} and −dP/dt_{min} in the control hearts were decreased to 49.2 ± 3.6% and 47.0 ± 2.7% compared to baseline levels, respectively. Both concentrations of U50488H significantly increased +dP/dt_{max} (77.9 ± 5.5% in U50-1 and 78.0 ± 4.3% in U50-10, P = 0.005 and 0.001 vs. control, respectively). The treatment of 10 μM U50488H effectively improved −dP/dt_{min} (64.7 ± 4.8%, P = 0.003) compared to the control hearts (47.0 ± 2.7%).

DISCUSSION

There remains controversy regarding the role of κ-OR agonists in myocardial I/R injury. Previous studies have demonstrated that pharmacological preconditioning with a κ-OR agonist bremazocin increased infarct size and another κ-OR agonist U50488H exacerbated ischemic-reperfusion arrhythmias following coronary occlusion in the isolated rat hearts. Conversely, Peart et al. demonstrated that exogenously application of three different κ-OR agonists (U50488H, ICI204448, and BRL52537) 10 min before the onset of ischemia reduced infarct size in intact myocardial infarction rat models. Taken together, these results do not completely rule out roles for κ-OR agonists in...
cardioprotection. However, most of the studies to investigate the role of OR agonists in myocardial I/R injury thus far were mainly focused on the nonspecific OR agonist or δ-OR agonist. Furthermore, there is scanty literature that have investigated the effects of a κ-OR agonist U50488H administered solely at reperfusion.

In our present study, the AN/AAR in control hearts was 27.2 ± 1.2%. Although the AN/AAR in our control hearts was smaller than those reported by others, this is in agreement with our recently reported study. Although the exact reason for this discrepancy is unknown, differences in the determination of risk and infarct area may account for it. U50488H given at early reperfusion phase was shown to significantly reduce myocardial infarction in our isolated rat hearts. These results are consistent with a recent report by Gross group, which showed that either δ- or κ-OR agonist administered as a single bolus 5 min before reperfusion could provide infarct size sparing effects in intact rat heart. Combined with our data, it is strongly suggested that κ-OR agonist U50488H targeting the reperfusion phase may play a role to prevent lethal reperfusion injury.

While treatment of κ-OR agonists during the reperfusion phase provides anti-infarct effects, little is known about its cardiodynamic effect following reperfusion. Recently, Wang et al. reported that Post-C improved the cardiodynamic parameters via activating κ-OR and mKATP by indirect antagonist study. Peart and Gross reported that U50488H confers cardioprotection with respect to LVDP, +dP/dt\text{max}, and −dP/dt\text{min} in isolated mice hearts undergoing 20 min global ischemia followed by 45 min reperfusion. However, it is not clear whether the contractile recovery after reperfusion is caused by the treatment prior to the ischemic period or due to its effects during the reperfusion period in their study (they used U50488H for 10 min prior to global ischemia and resumed it at the onset of reperfusion). Therefore, we investigated the functional recovery effects by κ-OR agonist U50488H targeting only the reperfusion period. Both concentrations of U50488H (1 and 10 μM) given at early reperfusion phase significantly improved the functional recovery of LVDP, RPP, +dP/dt\text{max}, and −dP/dt\text{min} after 2 hrs of reperfusion in our study. The LVDP recovered to more than 80% of its baseline levels by U50488H. The maximum and minimum of the first derivative of left ventricular pressure were significantly improved up to 46% compared to control hearts by U50488H after 2 hrs of reperfusion. The functional recovery was greater in the 10 μM U50488H. However, one should take into consideration that the higher concentration may lead to more undesirable effects.

In summary, a κ-OR agonist U50488H given at early reperfusion could significantly reduce both infarct size and myocardial stunning in isolated rat hearts. These results may benefit future clinical strategies when treating patients with ischemic heart disease.

REFERENCES

1. Gross ER, Hsu AK, Gross GJ: Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reper-

Fig. 4. Recovery of the maximum (+dP/dt\text{max}) and minimum (−dP/dt\text{min}) of first derivative of left ventricular pressure after 2 hrs reperfusion in isolated rat hearts. Rat hearts were subjected to control and treated with 1 (U50-1) or 10 (U50-10) μM U50488H. U50488H treatment at reperfusion significantly enhanced the recovery of the +dP/dt\text{max} and −dP/dt\text{min}. Value are expressed as means ± SEM. *: P < 0.05 vs. control.
12. Wong TM, Lee SY, Tai KK: Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart—an attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis. J Mol Cell Cardiol 1990; 22: 1167-75.